Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), inhibits tumor cell motility. However, the underlying mechanism is poorly understood. Here, we show that rapamycin inhibited type I insulin-like growth factor (IGF-I)-stimulated motility of a panel of cell lines. Expression of a rapamycin-resistant mutant of mTOR (mTORrr) prevented rapamycin inhibition of cell motility. However, cells expressing a kinase-dead mTORrr remained sensitive to rapamycin. Downregulation of raptor or rictor by RNA interference (RNAi) decreased cell motility. However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1. Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin. Further, IGF-I failed to stimulate motility of the cells, in which S6K1 was downregulated by RNAi. Moreover, downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) by RNAi-attenuated rapamycin inhibition of cell motility. In contrast, expression of constitutively active 4E-BP1 dramatically inhibited IGF-I-stimulated cell motility. The results indicate that both S6K1 and 4E-BP1 pathways, regulated by TORC1, are required for cell motility. Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.
Introduction
The mammalian target of rapamycin (mTOR), a 289 kDa Ser/Thr kinase, lies downstream of phosphatidylinositol 3 0 -kinase (PI3K), and senses mitogenic stimuli, nutrient conditions (Hara et al., 2002; Kim et al., 2002) and ATP (Dennis et al., 2001) , and regulates multiple cellular events required for cellular growth (size) and proliferation (Fingar et al., 2002; Martin and Hall, 2005) , differentiation (Erbay and Chen, 2001; Shu et al., 2002) , and survival (Hosoi et al., 1999; Beuvink et al., 2005) . Dysregulation of PI3K-mTOR pathway generates a favorable oncogenic environment and has been seen in a variety of transformed cells and human tumors, including rhabdomyosarcoma, lung, bladder, renal, ovary, breast, prostate, gastric, pancreatic, head and neck carcinomas, lymphoma, melanoma, glioma and other brain malignancies (Huang and Houghton, 2003) . Tumor cells in which PI3K-mTOR signaling is dysregulated are more susceptible than normal cells to inhibition of mTOR (Huang and Houghton, 2003) , suggesting mTOR inhibitors as potential tumor-selective therapeutic agents.
Rapamycin and its derivatives CCI-779, RAD001 and AP23573 (designated rapamycins) are the best-known inhibitors of mTOR and are in clinical trials as novel anticancer agents (Rowinsky, 2004) . These agents share a common mechanism of action and inhibit the function of the mTOR (Bjornsti and Houghton, 2004) . Rapamycin first forms a complex with a 12 kDa cytosolic protein designated FK-506-binding protein 12 and this complex binds mTOR and inhibits its function. p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) are two best-characterized downstream effector molecules of mTOR (Bjornsti and Houghton, 2004) . mTOR phosphorylates 4E-BP1 (Thr37/Thr46 and possibly Ser65 and Thr70) (MotheSatney et al., 2000; Gingras et al., 2001 ) and S6K1 (Thr389) (Dennis et al., 1996; von Manteuffel et al., 1997) . Inhibition of mTOR by rapamycin results in hypophosphorylation of 4E-BP1 (Brunn et al., 1997; Mothe-Satney et al., 2000; Gingras et al., 2001) . Subsequently, hypophosphorylated 4E-BP1 tightly binds to eIF4E, and prevents association of eIF4E with eIF4G and formation of the eIF4F initiation complex, thereby inhibiting cap-dependent translation of mRNA. In addition, inhibition of mTOR by rapamycin inactivates S6K1, blocking translation of mRNA species containing 5 0 terminal oligopyrimidine tracts (Dennis et al., 1996; von Manteuffel et al., 1997) , though this remains controversial (Tang et al., 2001; Stolovich et al., 2002) . Recently, two mTOR complexes (TORC1 and TORC2) have been identified (Hara et al., 2002; Kim et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004) . TORC1 consists of mTOR, mLST8 (also termed Gprotein b-subunit-like protein, GbL, a yeast homolog of LST8), and regulatory-associated protein of mTOR (raptor), and rapamycin sensitive, whereas TORC2 is composed of mTOR, mLST8, and rapamycin-insensitive companion of mTOR (rictor), and rapamycininsensitive (Jacinto et al., 2004; Sarbassov et al., 2004) . TORC1 regulates phosphorylation of S6K1 and 4E-BP1 (Hara et al., 2002; Kim et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004) and controls translation initiation, ribosome biogenesis and other growth-related events. TORC2 phosphorylates Akt at S473 (Sarbassov et al., 2005) , and regulates actin cytoskeleton (Loewith et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004) . Although the function of the two mTOR complexes remains to be determined, studies have demonstrated that exposure to rapamycin reduces overall protein synthesis only B15-20% but results in a specific G 1 accumulation in many cell lines. Thus, evidence suggests that rapamycin inhibits cell proliferation and growth by targeting TORC1-mediated S6K1 and 4E-BP1/eIF4E pathways (Bjornsti and Houghton, 2004) .
While intensive studies have focused on the antiproliferative activity of rapamycins, their inhibitory effect on cell motility is only beginning to be recognized. Recently, inhibition of motility or invasion by rapamycin has been described in porcine, murine and human aortic smooth muscle cells (Poon et al., 1996; Sun et al., 2001; Sakakibara et al., 2005) , canine kidney epithelial cells (MDCKT23) and human colorectal cells (HCT-8/ S11) (Attoub et al., 2000) , Swiss 3T3 fibroblasts (Berven et al., 2004) , trophoblast (SGHPL-4) (Cartwright et al., 2002) , neutrophils (Gomez-Cambronero, 2003) , ovarian cells (Wong et al., 2004) , and human umbilical vein endothelial cells (Kwon et al., 2005) in culture. In vivo, rapamycin also potently inhibits metastases of transplanted tumors derived from murine adenocarcinoma cells (CT-26) (Guba et al., 2002) , human renal cancer cells (RCC 786-O) (Luan et al., 2003) , murine nonsmall-cell lung cancer cells (KLN-205) (Boffa et al., 2004) and osteosarcoma (K7M2) (Wan et al., 2005) in mice. The data indicate that rapamycin is a potent inhibitor not only for cell proliferation, growth, and survival but also for cell motility. Studies have demonstrated that rapamycin inhibits proliferation and growth (size) by suppression of mTOR-mediated S6K1 and 4E-BP1/eIF4E pathways (Fingar et al., 2002; Bjornsti and Houghton, 2004; Fingar et al., 2004) , induces apoptosis of cells through downregulation of mTOR-mediated 4E-BP1/eIF4E pathway , and inhibits differentiation of C2C12 cells in an mTOR-kinase activity-independent manner (Erbay and Chen, 2001) , despite existence of controversy (Shu et al., 2002) . However, the underlying mechanism of rapamycin inhibition of cell motility remains poorly understood.
The type I insulin-like growth factor (IGF-I) receptor (IGF-IR) and its ligands, IGF-I and IGF-II, play critical roles in the regulation of cellular proliferation, survival and transformation (Bjornsti and Houghton, 2004) . Increasing evidence indicates that IGF-I signaling is also pivotal to cell motility and invasion (LeRoith and Roberts, 2003) . For example, activation of IGF-IR and subsequent activation of PI3K and mitogen-activated protein kinase pathways induces motility of neuroblastoma cells (Meyer et al., 2001) . By affecting integrin relocation and association of the E-cadherin/catenin complex with the cytoskeleton, IGF-I stimulates migration of epithelial colonic cells (Andre et al., 1999) and myeloma cells (Tai et al., 2003) . IGF-IR controls lung carcinoma cell motility and invasion by coordinately regulating expression and activation of matrix metalloproteinase-2 (Zhang and Brodt, 2002) . IGFs are also potent stimulators of rhabdomyosarcoma cell motility (El-Badry et al., 1990; Minniti et al., 1992; Gallicchio et al., 2003) . Therefore, IGF-I signaling contributes to metastatic phenotypes in various types of tumors.
Here, we show that rapamycin inhibited IGF-Istimulated motility of a panel of cell lines, such as human rhabdomyosarcoma (Rh1 and Rh30), breast carcinoma (MDA-MB-468), cervical adenocarcinoma (HeLa), and SV40 transformed African green monkey kidney fibroblast (COS-1) cells in culture. Our data suggest that rapamycin inhibits IGF-I-stimulated cell motility, through suppression of TORC1-mediated S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.
Results
Rapamycin inhibits IGF-I or 10% fetal bovine serumstimulated cell motility Rhabdomyosarcoma cells were primarily chosen as models to study IGF-I-mediated cell motility, because dysregulation of IGF-I signaling has been well characterized in these childhood tumor cells (El-Badry et al., 1990; Minniti et al., 1992; Shapiro et al., 1994) . There exist high levels of IGF-I receptor in RMS cells (Shapiro et al., 1994) . Under autocrine conditions, rhabdomyosarcoma cells are able to produce large quantity of IGF-II, which has approximately equal affinity to IGF-I receptor as IGF-I (El-Badry et al., 1990) . As seen in many other cell lines with dysregulated IGF-I signaling, rhabdomyosarcoma cells are extremely susceptible to rapamycin in growth inhibition (IC 50 ¼ 1-3 nM) (Hosoi et al., 1998) . Since IGFs (IGF-I and IGF-II) promote the motility of rhabdomyosarcoma cells (El-Badry et al., 1990; Minniti et al., 1992; Gallicchio et al., 2003) , we determined whether rapamycin also inhibits motility of rhabdomyosarcoma cells. Using the wound-healing assay, we found that Rh1 and Rh30 (two rhabdomyo-sarcoma cell lines) migrated under autocrine (serum free) conditions as RD (another rhabdomyosarcoma cell line) cells did (El-Badry et al., 1990) . Rapamycin inhibited the basal or IGF-I-stimulated motility of Rh1 and Rh30 cells in a concentration-dependent manner (data not shown). Rapamycin significantly inhibited the cell motility starting at 10 ng/ml. However, treatment with rapamycin at higher concentrations (>1000 ng/ml) for 24 h resulted in considerable cytotoxicity (20-40% of cells positive for trypan blue staining). Therefore, we selected 100 ng/ml of rapamycin for the cell motility assays. At this concentration, rapamycin inhibited the basal or IGF-I-stimulated cell motility by 60-70% (Figure 1 ). IGF-I stimulated the motility of rhabdomyosarcoma cells by B3-fold, and this was dramatically attenuated by rapamycin to or below the basal level (Figure 1) .
Since a long-term (24 h) wound-healing assay cannot well-distinguish cell proliferation and survival from cell migration (Rodriguez et al., 2005) , to confirm rapamycin inhibition of cell motility, we performed more rigorous cell motility assays, including the Transwell assay (Boyden chamber assay) (Hassid et al., 1999 ) and the single cell motility assay using colloidal gold particle-coating plates (Takaishi et al., 1995) . Consistently, a striking inhibition of IGF-I-stimulated rhabdomyosarcoma cell motility by rapamycin was also observed by the Transwell assay (Figure 2 ) and the single cell motility assay (Figure 3) .
The data from the single cell motility assay have clearly demonstrated that rapamycin inhibition of cell motility is not due to its antiproliferative effect. Further, our results also indicate that rapamycin inhibition of cell motility is independent of its cytotoxicity. Rapamycin is cytostatic in many cell lines and also cytotoxic in some cases (Hosoi et al., 1999) . Rapamycin (100 ng/ml) can induce apoptosis of Rh1 and Rh30 cells, but the death only occurred 4-6 days of post-exposure (Hosoi et al., 1999; . In this study, treatment with rapamycin (100 ng/ml) for 24 h did not alter the viability of the cells tested, as non-treated and treated cells did not show any difference in staining by trypan blue dye exclusion. Approximately, 97% of cells excluded dye.
Further, our data indicate that rapamycin inhibition of IGF-I-stimulated cell motility is not cell type dependent, because similar results were also seen in other cell lines, including MDA-MB-468 (breast carcinoma), HeLa (cervical adenocarcinoma), COS-1 (monkey kidney fibroblasts) (Figure 2 ), NIH3T3 (murine fibroblasts), PC-3 (prostate carcinoma), and SH-SY5Y (neuroblastoma) (data not shown).
Under in vivo conditions, besides IGF-I, other growth factors/hormones (e.g. epidermal growth factor, plateletderived endothelial cell growth factor, human growth factor, insulin, etc.) may also stimulate cell motility. To examine whether rapamycin still inhibits cell motility under more complicated conditions, we examined the effect of rapamycin on 10% fetal bovine serum (FBS)-stimulated cell motility, since there exist a pool of growth factors, hormones and other potential stimuli in the serum. As shown in Figure 3 , 10% FBS stimulated motility of Rh30 and HeLa cells more potently than IGF-I, probably due to additive or synergistic effects of more stimuli in the serum. Of interest, rapamycin also potently inhibited 10% FBS-stimulated motility of Rh30 and HeLa cells.
Rapamycin inhibits cell motility in an mTOR kinase activity-dependent manner Since a kinase activity-independent function for mTOR in the regulation of cell differentiation has been reported (Erbay and Chen, 2001 ), we next examined whether rapamycin inhibits cell motility by inhibiting the kinase activity of mTOR. For this, we established Rh30 clones stably expressing an empty vector (pcDNA), a plasmid encoding an AU1 epitope-tagged rapamycin-resistant but kinase active mTOR (S2035I, designated rapamycinresistant mutant of mTOR (mTORrr)) or kinase-dead mTORrr (S2035I/D2338A, designated mTOR-SIDA) (Sekulic et al., 2000) , respectively ( Figure 4a ). When the cells were pretreated with rapamycin (100 ng/ml) for 2 h, followed by stimulation with IGF-I (10 ng/ml) for 1 h, expression of mTORrr, but not mTOR-SIDA, prevented rapamycin inhibition of phosphorylation of S6K1 (T389) and 4E-BP1 (Figure 4a ), the two bestcharacterized downstream effector molecules of mTOR. The data indicate that mTORrr functions as a rapamycin-resistant mutant, and mTOR-SIDA as a kinase-dead mutant in Rh30 cells, as seen in other cell lines (Sekulic et al., 2000; Shu et al., 2002) .
Studies have shown that expression of mTORrr does not alter the growth rate of Rh1, Rh30 and C2C12 cells (Hosoi et al., 1999; Shu et al., 2002; . Similarly, we did not observe a significant difference of cell motility between mTORrr or mTOR-SIDA transfectants and control cells (including the parental cell lines and the transfectants with pcDNA empty vector) (data not shown). Using these cells, we performed the wound-healing assay. Consistently, expression of mTORrr, but not mTOR-SIDA, prevented rapamycin inhibition of IGF-I-stimulated motility of Rh30 cells ( Figure 4b ). The results strongly suggest that rapamycin inhibition of IGF-I-stimulated cell motility is a consequence of inhibition of mTOR kinase activity. Jacinto et al., 2004; Sarbassov et al., 2004) . Disruption of TORC2 inhibits cell spreading and F-actin polymerization of NIH3T3 cells (Jacinto et al., 2004) , suggesting that the TORC2 may be crucial for cell motility. However, TORC2 is rapamycin insensitive (Jacinto et al., 2004; Sarbassov et al., 2004) . As described above, we have found that rapamycin inhibits cell motility in mTOR kinase activity-dependent manner. Therefore, we reasoned involvement of TORC1 in the regulation of cell motility. To this end, lentiviral shRNA to raptor was used to silence raptor expression in Rh30 cells. shRNA to raptor, but not the control shRNA to green fluorescent protein (GFP), downregulated protein level of raptor by B90% (vs control) in the cells (Figure 5a ). Consistent with previous findings (Jacinto et al., 2004; Sarbassov et al., 2004) , downregulation of raptor blocked mTOR-mediated phosphorylation of S6K1 and 4E-BP1, mimicking the effect of rapamycin in Rh30 cells (Figure 5b ). Of particular interest, downregulation of raptor also significantly inhibited IGF-I or 10% FBS-stimulated motility of Rh30 cells, as detected by the single cell motility assay (Figure 5c ) or the Transwell assay (data not shown). Taken together, the data suggest a crucial role of rapamycin-sensitive TORC1 in the regulation of cell motility.
As a control, rictor in Rh30 cells was downregulated by B90% (vs control) using lentiviral shRNA to rictor (Figure 6a ). Downregulation of rictor did not affect IGF-stimulated phosphorylation of S6K1 and 4E-BP1 (Figure 6b), as described by others (Jacinto et al., 2004; Sarbassov et al., 2004) . As expected, downregulation of rictor did also suppress IGF-I or 10% FBS-stimulated cell motility (Figure 6c ). The results indicate that both TORC1 and TORC2 control cell motility. However, rapamycin inhibition of cell motility is probably only by targeting TORC1 signaling.
S6K1 is essential for mTOR-mediated cell motility
Since S6K1 is one of the best-characterized downstream effector molecules of TORC1, next, we determined whether rapamycin inhibits cell motility through targeting S6K1 pathway. For this, Rh30 cells were infected with recombinant adenoviruses expressing hemagglutinin (HA)-tagged wild-type (wt) S6K1 (Ad-S6K1-wt), constitutively active and rapamycin-resistant S6K1 mutant (F5A-E389-R3A) (Ad-S6K1-ca) and control virus encoding GFP alone. As shown in Figure 7a , Western blot analysis revealed high levels of recombinant S6K1-wt or S6K1-F5A-E389-R3A in the cells infected with Ad-S6K1-wt or Ad-S6K1-ca, but not in the cells infected with Ad-GFP. Noticeably, cells expressing constitutively active and rapamycin-resistant S6K1 (S6K1-F5A-E389-R3A), but not wild-type S6K1 or GFP, are resistant to rapamycin inhibition of phosphorylation of S6 ribosomal protein (p-S6), a substrate of S6K1, as expected. Similarly, cells expressing constitutively active S6K1 (S6K1-F5A-E389-R3A), but not wild-type S6K1 or GFP, are resistant to rapamycin inhibition of IGF-I-stimulated cell motility (Figure 7b) , as determined by the single cell motility assay. The data suggest that mTOR controls cell motility, at least, in part through S6K1 pathway. To further test whether S6K1 is essential for TORC1-mediated cell motility, lentiviral shRNA to S6K1 was used to downregulate S6K1 in Rh30 cells. As shown in Figure 8a , infection of Rh30 cells with lentiviral shRNA to S6K1 for 5 days silenced expression of cellular S6K1 protein by B80%, comparing with control cells (infected with lentiviral shRNA to GFP). In agreement with this, downregulation of S6K1 protein resulted in suppression of S6K1 kinase activity, as detected by Western blot with antibodies to phospho-S6K1 (T389) and phospho-S6 ribosomal protein (S235/236), respectively (Figure 8a) . Consequently, IGF-I failed to stimulate the motility of Rh30 treated with S6K1 shRNA, as detected by the single cell motility assay (Figure 8b) . The results indicate that S6K1 pathway is necessary for mTOR-mediated cell motility.
Downregulation of 4E-BP1 attenuates rapamycin inhibition of cell motility Next, we determined whether the other best-known downstream signaling pathway of TORC1, 4E-BP1/ eIF4E, is involved in rapamycin inhibition of cell motility. Since suppression of eIF4E-dependent translation is determined by the relative abundance of 4E-BP1 and eIF4E in cells, mTOR regulation of this pathway can be abrogated by overexpression of eIF4E or downregulation of 4E-BP1, the suppressor of eIF4E. We observed that cellular protein levels of eIF4E were about 3-5 fold higher in all cell lines tested (Rh1, Rh30, PC-3, MDA-MB-468, MCF-7, SH-SY5Y, NIH3T3, HeLa and COS-1), comparing with normal cells (wildtype mouse embryonic fibroblasts and MCF10A). It was hard to overexpress eIF4E in the cells by transfection. Consequently, we chose to downregulate 4E-BP1 in the cells. Similar to our previous findings , piNEO/4E-BP1 shRNA-silenced expression of 4E-BP1 by about 80% in pools of clones of Rh30/4E-BP1 shRNA cells, in comparison with that in parental Rh30, or pools of clones (Rh30/V) stably expressing a vector control plasmid (piNEO) (Figure 9a ). Interestingly, when 4E-BP1 is downregulated, rapamycin inhibition of both basal and IGF-I-stimulated cell Figure 8 IGF-I failed to stimulate motility of Rh30 cells, in which S6K1 was downregulated. (a) Lentiviral shRNA to S6K1-downregulated S6K1 and its activity. Rh30 cells were infected with lentiviral shRNAs to S6K1 and GFP (for control), as described in Materials and methods. Cells were serum starved for 24 h, and then treated with or without rapamycin (Rapa, 100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml) for 1 h. p-S6K1 (T389), S6K1, phospho-S6 (S235/236), S6 and b-tubulin in the cell lysates were determined by Western blot. (b) Motility of Rh30 cells, after infected with lentiviral shRNAs to S6K1 and GFP (as control), was determined by the single cell motility assay. motility was dramatically attenuated (Figure 9b) . The results imply that rapamycin inhibits cell motility also at least partially by targeting 4E-BP1/eIF4E-signaling pathway.
Expression of constitutively hypophosphorylated 4E-BP1 inhibits IGF-I-stimulated cell motility
To further demonstrate the role of 4E-BP1/eIF4E pathway in the TORC1-mediated cell motility, we generated recombinant adenovirus encoding HA-tagged 4E-BP1 mutants where Thr36, Thr45, Ser64, Thr69 and Ser82 are replaced by Ala residues (designated 4EBP1-5A) mimicking hypophosphorylated residues, thus tightly binding to and sequester eIF4E in cells (MotheSatney et al., 2000) . Subsequently, Rh30 cells were infected with Ad-4EBP1-5A or Ad-GFP (as control). As shown in Figure 10a , HA-tagged 4E-BP1 and higher levels of 4E-BP1 were detected in Ad-4EBP1-5A-infected cells. Treatment with rapamycin failed to change the mobility of 4E-BP1-5A (Figure 10a , upper panel). However, using 7-methyl GTP-Sepharose pulldown assay, very striking amount of recombinant 4E-BP1-5A was found to bind to eIF4E, even in the absence of rapamycin (Figure 10a, bottom panel) . The data clearly indicate that Ad-4EBP1-5A functions as a dominant suppressor of eIF4E in the cells. Finally, Ad-4EBP1-5A-or Ad-GFP-infected Rh30 and HeLa cells were subject to the single cell motility assay. As shown in Figure 10b , IGF-I failed to stimulate motility of Ad-4EBP1-5A-infected Rh30 cells. Similar results were also seen in HeLa cells (data not shown). The findings suggest that 4E-BP1/eIF4E pathway is as critical as S6K1 pathway for TORC1-mediated cell motility.
Since mTOR controls protein synthesis via S6K1 and 4E-BP1/eIF4E pathways (Bjornsti and Houghton, 2004; Martin and Hall, 2005) , to check whether there is a clue that rapamycin inhibition of protein synthesis contributes to its inhibition of cell motility, as a control, Rh30 cells were treated with cycloheximide, a translational inhibitor. We found that treatment with cycloheximide (50 mM) inhibited the basal, IGF-I-or 10% FBSstimulated motility of Rh30 cells by B70%, as determined by the wound-healing assay or the single cell motility assay (data not shown). The results reveal that inhibition of protein synthesis would potently reduce cell motility. Rapamycin inhibition of cell motility may partially attribute to its inhibition of protein synthesis, though other mechanisms may also be involved.
Discussion mTOR participates in the regulation of cell proliferation, growth, differentiation and survival (Bjornsti and Houghton, 2004; Martin and Hall, 2005) . A variety of transformed or tumor cells with dysregulated mTOR signaling have shown higher susceptibility to inhibitors of mTOR than normal cells, forming a rationale for mTOR inhibitors as potential tumor-selective therapeutic agents. Clinical trials have demonstrated that rapamycin analogs (CCI-779, RAD001 and AP23573) are promising anticancer drugs (Rowinsky, 2004) . They specifically block the function of mTOR, inhibiting growth of numerous solid tumors (renal, breast, prostate, colon and brain cancers) with only mild side effects (Rowinsky, 2004) . However, the anticancer mechanism of rapamycins remains obscure. While intensive studies have focused on the antiproliferative activity of rapamycins, their inhibitory effect on cell motility is only beginning to be recognized. Here we show that rapamycin potently inhibits IGF-I-or 10% FBS-stimulated motility of a panel of cell lines, such as and Ad-GFP (as control), were treated with or without rapamycin (Rapa, 100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml) for 1 h. Western blot was performed using antibodies to HA, 4E-BP1 and b-tubulin (for loading control), respectively (upper panel). 4E-BP1-eIF4E binding was determined by pull-down with 7-methyl GTP-Sepharose, followed by immunoblotting with antibodies to eIF4E and 4E-BP1, respectively (bottom panel). (b) Motility of Rh30 cells, infected with Ad-4EBP1-5A and Ad-GFP, was determined by the single cell motility assay. Results are means7s.d. and are pooled from three independent experiments. rhabdomyosarcoma (Rh1 and Rh30), cervical adenocarcinoma (HeLa), and SV40 transformed African green monkey kidney fibroblast (COS-1) cells in culture. The data suggest a pivotal role of mTOR not only in cell proliferation but also in cell motility.
It is well known that rapamycin specifically inhibits the kinase activity of mTOR, and potently inhibits tumor cell proliferation by slowing transit or arresting cells in the G 1 phase of the cell cycle (Bjornsti and Houghton, 2004) , or under certain conditions by inducing apoptosis (Hosoi et al., 1999; . However, recent studies have shown that rapamycin inhibits differentiation of C2C12 cells (Erbay and Chen, 2001) , which is independent of the kinase activity of mTOR, though this remains controversial (Erbay and chen, 2001; Shu et al., 2002) . This prompted us to study whether rapamycin inhibits cell motility in the same manner as it inhibits cell differentiation. We found that expression of a rapamycin-resistant mutant mTOR (S2035I), mTORrr, that prevents binding of FKBP-rapamycin but has intact kinase activity, but not kinase-dead mTORrr (S2035I/D2338A) (mTOR-SIDA) (Sekulic et al., 2000) , rescued rapamycin inhibition of IGF-I-stimulated motility of Rh30 cells (Figure 4b) . The results strongly suggest that rapamycin inhibition of IGF-I-stimulated cell motility is a consequence of inhibition of the kinase activity of mTOR. This is in agreement with the data observed in rapamycin inhibition of cell proliferation, growth and survival.
Recently, two mTOR complexes (mTOR-raptor, TORC1 and mTOR-rictor, TORC2) have been identified (Hara et al., 2002; Kim et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004) . TORC1 regulates phosphorylation of S6K1 and 4E-BP1 (Hara et al., 2002; Kim et al., 2002; Jacinto et al., 2004; Sarbassov et al., 2004) , and TORC2 phosphorylates Akt at S473 (Sarbassov et al., 2005) . TORC1 is rapamycin sensitive, and controls translation, initiation, ribosome biogenesis and other growth-related events, whereas TORC2 is rapamycin insensitive, and regulates polarization of actin cytoskeleton (Jacinto et al., 2004; Sarbassov et al., 2004) . Here we show that disruption of TORC1 or TORC2 by RNA interference decreases cell motility, suggesting that both TORC1 and TORC2 regulate cell motility. Since TORC2 is rapamycin insensitive, we did not further study the mechanism involved. S6K1 and 4E-BP1/eIF4E are the two best-characterized downstream signaling pathways of TORC1 (Bjornsti and Houghton, 2004; Martin and Hall, 2005) . To further understanding the mechanism by which rapamycin inhibits cell motility, we evaluated the roles of these two downstream pathways in the regulation of cell motility. The levels or activities of S6K1 and 4E-BP1 were individually manipulated. Cells infected with a replication-deficient adenoviral recombinant expressing constitutively active and rapamycin-resistant mutant of S6K1 (F5A-E389-R3A), but not with an adenovirus expressing wild-type S6K1, or a control viral vector (Ad-GFP), conferred to resistance to rapamycin. Further, IGF-I failed to stimulate motility of Rh30 cells in which S6K1 was downregulated by shRNA. On the other hand, downregulation of 4E-BP1 by shRNAattenuated rapamycin inhibition of cell motility. In contrast, ectopic expression of constitutively hypophophorylated 4E-BP1 (4E-BP1-5A) dramatically inhibited IGF-I-stimulated cell motility. The findings indicate that both S6K1 and 4E-BP1/eIF4E pathways are essential for cell motility. Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1-and 4E-BP1/eIF4E-signaling pathways. Our results are the first to suggest that rapamycin inhibits cell motility by a mechanism similar to that by which rapamycin inhibits cell proliferation in mammalian cells.
4E-BP1 primarily functions as a suppressor of eIF4E. Hypophosphorylated 4E-BP1 tightly binds to eIF4E, and prevents association of eIF4E with eIF4G and formation of the eIF4F initiation complex, thereby inhibiting cap-dependent translation of mRNA (MotheSatney et al., 2000; Gingras et al., 2001) . S6K1 is thought to be primarily responsible for translation of mRNA species containing 5 0 terminal oligopyrimidine tracts (Dennis et al., 1996; von Manteuffel et al., 1997) , though this remains controversial (Tang et al., 2001; Stolovich et al., 2002) . Both S6K1 and 4E-BP1/eIF4E pathways are related to translation (Holz et al., 2005) . It is not clear how rapamycin inhibition of these two pathways results in inhibition of cell motility. Cell migration is a highly orchestrated multi-step process, including polarization, protrusion, adhesion and deadhesion (Ridley et al., 2003) . Many proteins, such as Rac/cdc42, atypical protein kinase C, integrins, focal adhesion kinase, Src, and extracellular signal-regulated kinase 1/2, participate in this process. Whether rapamycin inhibits cell motility by impacting those proteins at transcriptional, translational or post-translational level remains to be defined. Clearly, more studies are required to address the question.
In summary, our cell motility assays demonstrate that rapamycin inhibits cell motility, which is independent of cell type and stimuli. Rapamycin inhibition of cell motility is a consequence of inhibition of mTOR kinase activity, and results from inhibition of signaling to S6K1 and 4E-BP1/eIF4E pathways downstream of TORC1.
Materials and methods

Cell lines and cultures
Cell lines from human rhabdomyosarcoma (Rh1 and Rh30) (from Dr Peter J Houghton, St Jude Children's Research Hospital, Memphis, TN, USA) were grown in antibiotic-free RPMI 1640 medium (Mediatech, Herndon, VA, USA) supplemented with 10% FBS (Hyclone, Logan, UT, USA) at 371C and 5% CO 2 . Human breast carcinoma (MDA-MB-468), cervical adenocarcinoma (HeLa), prostate carcinoma (PC-3), and neuroblastoma (SH-SY5Y) cells, SV40-transformed African green monkey kidney fibroblasts (COS-1), and murine fibroblasts (NIH 3T3) (American Type Culture Collection, Manassas, VA, USA) were grown in antibiotic-free Dulbecco'smodified Eagle medium (DMEM) (Mediatech, Herndon, VA, USA) supplemented with 10% bovine calf serum at 371C and 5% CO 2 . For experiments where cells were deprived of serum, cell monolayers were washed with phosphate-buffered saline (PBS), and incubated in the serum-free DMEM (Mediatech, Herndon, VA, USA).
Plasmids and transfection of cells
The expression vectors encoding AU1-tagged mTORrr (Hosoi et al., 1999) and mTOR-SIDA (Sekulic et al., 2000) were generously provided by Robert T Abraham (Burnham Institute, La Jolla, CA, USA). mTORrr represents the entire mTOR gene with the site mutation (S2035I) that has intact mTOR kinase activity, but prevents FKBP12-rapamycin complex binding and is rapamycin resistant (Hosoi et al., 1999) . mTOR-SIDA stands for a catalytically inactive (kinase dead) mTORrr mutant (D2038A) (Sekulic et al., 2000) . Rh1 and Rh30 cells (5 Â 10 5 cells) in six-well plates were transfected with the plasmids expressing mTORrr, mTOR-SIDA or with pcDNA3 control vector (Invitrogen, Carlsbad, CA, USA) by using TransIT s -LT1 transfection reagent (Mirus, Madison, WI, USA) as directed by the manufacturer. After transfection for 48 h, cells were transferred to 100-mm dishes and cultured for 2 weeks at 371, 5% CO 2 in growth medium containing 500 mg/ml geneticin (G418 sulfate; Invitrogen). Drug-resistant cells were cloned and expanded in growth medium containing G418 (500 mg/ml). Individual clones were screened for expression of the mutant proteins by Western blot analysis with anti-AU1 antibodies (Bethyl Laboratories, Montgomery, TX, USA). A short hairpin-activated gene silencing strategy was used for shRNA to downregulate 4E-BP1, as described previously . Briefly, Rh30 cells were transfected with piNEO/4E-BP1 shRNA or piNEO (empty vector for control) (gifts from Dr Peter J Houghton, St Jude children's Research Hospital, Memphis, TN, USA) using Fugene 6 (Roche Diagnostics, Indianapolis, IN, USA). G418-resistant clones (piNEO and piNEO/4E-BP1 shRNA) were pooled, and analysed by Western blot with antibodies to 4E-BP1 (Zymed, South San Francisco, CA, USA). Empty vector piNEO did not affect expression of 4E-BP1, whereas piNEO/ 4E-BP1 shRNA reduced expression of 4E-BP1 by about 80%. Both piNEO and piNEO/4E-BP1 shRNA cells were expanded and used for experiments.
Recombinant adenoviral constructs and infection of cells
Constitutively hypophosphorylated 4E-BP1 (4E-BP1-5A) was excised with HindIII/Xba1 from the expression vector pCMV4/ 4E-BP1-5A (a gift from John C Lawrence, University of Virginia School of Medicine, Charlottesville, VA, USA) encoding constitutively hypophosphorylated mutant 4E-BP1 (T36A, T45A, S64A, T69A and S82A) (Mothe-Satney et al., 2000) and tagged with HA epitope at N-terminus by polymerase chain reaction (PCR). The recombinant adenoviruses encoding HA-tagged 4E-BP1-5A (Ad-4EBP1-5A) was generated using AdEasy s system (He et al., 1998) (American Type Culture Collection, Manassas, VA, USA) as directed by the supplier. Constitutively active and rapamycin-resistant S6K1 (pRK7/HA-S6K1-F5A-E389-R3A) was constructed, as described previously (Schalm et al., 2005) . To make adenoviral construct expressing this mutant, a fragment of the HA-tagged mutant S6K1 was amplified via PCR using the follow primers: HAF, 5 0 -AACCGGTACCATGTACCCATACGATGTTCC AGAT-3 0 and S6K1RE, GTTCGATATCTCATAGATTCA TACGCAGGTGC-3 0 , and then inserted into the PENTR11 shuttle vector (Invitrogen) between the Kpn1/EcoRV restriction enzyme site. Recombinant adenovirus encoding HA tagged the constitutively active and rapamycin-resistant S6K1 (Ad-S6K1-ca) was generated and amplified using the ViraPowert Adenoviral Expression System (Invitrogen, Carsbad, CA, USA), following the manufacturer's instruction. The recombinant adenovirus (Ad-S6K1-wt) encoding HA-tagged wild-type S6K1 was prepared, as described previously (Martin et al., 2004) . These viruses were co-expressing GFP, and titrated by visualization of GFP expression in HEK 293 cells 24 h post-infection under a fluorescence microscope (Nikon TE300). For experiments, Rh1 and Rh30 cells were grown in six-well plates in RPMI 1640 medium supplemented with 10% FBS, and infected with the individual adenovirus for 24 h at 1 of multiplicity of infection (MOI ¼ 1). Subsequently, cells were washed with PBS and serum starved in DMEM for 24 h before experiments. The virus (Ad-GFP) encoding GFP alone served as a control. Expression of HA-tagged 4E-BP1-5A, S6K1-wt, or S6K1-F5A-E389-R3A was determined by Western blot with antibodies to HA (Roche Diagnostics, Indianapolis, IN, USA). The function of 4E-BP1-5A was examined by analysis of 4E-BP1-eIF4E binding using 7-methyl GTP Sepharose pull-down assay (Gingras et al., 1998) , whereas the function of S6K1-wt and S6K1-F5A-E389-R3A was determined by immunoblotting with antibodies to S6K1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and phospho-S6 ribosomal protein (Ser235/236) (Cell Signaling, Beverly, MA, USA), respectively.
Lentiviral shRNA cloning, production and infection
The sequences of the oligonucleotides were used as follows:
0 . The oligonucleotides were synthesized, annealed and inserted into a lentiviral shRNA expression vector FSIPPW (Kanellopoulou et al., 2005) (a gift from Dr Jun Chung, Louisiana State University Health Sciences Center, Shreveport, LA, USA), via the restriction enzyme site of BamH1/EcoR1. The restriction enzymes and T4 DNA ligase were from Promega (Madison, WI, USA). The lentivirus was packaged by cotransfection of 293TD cells with the shRNA expression vector, V-SVG and delta-VPR plasmid at the ratio of 2:2:1, using Lipofectamine 2000 reagent (Invitrogen). After transfection for 48 and 72 h, the supernatants containing lentiviral particles were harvested. Lentiviral shRNAs to raptor and rictor (Sarbassov et al., 2005) were gifts from Dr David M Sabatini (Massachusetts Institute of Technology, Cambridge, MA, USA). The lentivirus-expressing GFP-target shRNA (a gift from Dr Jun Chung, Louisiana State University Health Sciences Center, Shreveport, LA, USA) was used as control. Monolayer Rh30 or HeLa cells, when grown to about 70% confluence, were infected with above lentivirus-containing supernatant in the presence of 8 mg/ml polybrene and, exposed to 2 mg/ml puromycin after 24 h of infection. In 5 days, cells were used for experiments.
Western blot analysis
Western blot was performed, as described previously . We used primary antibodies to AU1 and raptor (Bethyl Laboratories), rictor (a gift of David Sabatini, Massachusetts Institute of Technology, Cambridge, MA, USA), HA (12CA5) (Roche Diagnostics), phospho-S6K1 (Thr389), S6K1 and eIF4E (Santa Cruz Biotechnology), 4E-BP1 (Zymed Laboratories, South San Francisco, CA, USA), phospho-4E-BP1 (Thr70), phospho-S6 ribosomal protein (Ser235/236) and S6 ribosomal protein (Cell Signaling), and b-tubulin (Sigma, St Louis, MO, USA). To semiquantitate the intensities of the bands, NIH ImageJ was used.
Analysis of 4E-BP1-eIF4E binding A functional assay of 4E-BP1 was performed, as described by Gingras et al. (1998) . Serum-starved cells (3 Â 10 6 cells/100-mm dish) were pre-treated with or without 100 ng/ml rapamycin for 1 h, followed by stimulation with or without IGF-I (10 ng/ ml; PeproTech, Rocky Hill, NJ, USA) for 1 h. The cells were scraped into 1 ml of ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM KCl, 1 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene-glycol-bis(2-aminoethyl ether)-N,N,N,N 0 -tetraacetic acid, 50 mM b-glycerophosphate, 10 mM sodium pyrophosphate, 50 mM NaF, 1 mM Na 3 VO 4 , 50 mM okadaic acid, 1 mM phenylmethylsulfonyl fluoride, and protease cocktail inhibitor (1:1000, Sigma). Lysis was accomplished by three freeze-thaw cycles. To pull-down eIF4E, 25 ml of 7-methyl GTP Sepharose (Amersham Biosciences, Piscataway, NJ, USA) was added to the lysates and incubated overnight on a rotator at 41C. The complexes were pelleted by centrifugation and washed three times with the lysis buffer. To release eIF4E from the beads, 50 ml of sodium, dodecyl sulfatepolyacrylamide gel electrophoresis loading buffer was added to the samples, which were then heated at 951C for 3 min. Samples were analysed by Western blot for 4E-BP1 and eIF4E, as described above.
Wound-healing assay A monolayer of cells were grown in six-well plates to 80% confluence, and serum starved in Dulbecco's modified Eagle's medium for 24 h. Cell motility was assessed by the woundhealing assay (Yuan et al., 2000) . Briefly, migration was initiated by removing a portion of the cell layer by scratching with a single-edge razor blade cut to B27 mm in length. The scratch began at the diameter of the dish and extended over an area B10 mm wide. The medium was changed to remove floating or damaged cells. Cells were pretreated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml, PeproTech) for 22 h. Cells migrated over the denuded area were observed and photographed with an Olympus inverted phase-contrast microscope equipped with Quick Imaging system. The number of cells migrating per millimeter of scratch was counted.
Transwell assay
Cell migration was evaluated using an 8-mm pore size Transwell system (Costar, Cambridge, MA, USA) as described (Hassid et al., 1999) , with a slight modification. Briefly, overnight serum-starved cells were pretreated with rapamycin (100 ng/ml) or vehicle (dimethyl sulfoxide) for 2 h, trypsinized with Tryplet Express (GIBCO, Grand Island, NY, USA), and resuspended in serum-free DMEM at a density of 5 Â 10 5 cells/ ml. The top chamber of transwell was loaded with 100 ml of cell suspension with or without rapamycin and the bottom chamber was loaded with 0.6 ml of DMEM containing IGF-I (10 ng/ml, PeproTech) or 10% FBS. After incubation at 371C in 5% CO 2 for 24 h, the filters were removed, rinsed two times with 0.1 M PBS (pH 7.4), fixed in 4% paraformaldehyde (dissolved in 0.1 M PBS, pH 7.4), and stained with 0.1% crystal violet. Cells on the upper side of the filter were wiped off with cotton swabs. Migrated cells on the lower side of the filter were determined by counting specified cross-sectional fields on the filters with a phase-contrast microscope using Â 200 original magnification.
Single cell motility assay The single cell motility assay was performed as described (Takaishi et al., 1995) . Briefly, six-well plates were coated with the colloidal gold particles. Serum-starved cells were trypsinized with Tryplet Express (GIBCO, Grand Island, NY, USA), and resuspended in serum-free DMEM at a density of 1 Â 10 3 cells/ml. Two milliliter of the cell suspension was added to each gold particle-coated well. After incubation at 371C in 5% CO 2 for 2 h, cells were pretreated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without IGF-I (10 ng/ml, PeproTech) or 10% FBS for 22 h. The gold colloidal particles were observed as a homogenous layer of fine black particles. When single cells migrated, they phagocytized and removed the gold particles, resulting in corresponding white tracks. The single migrating cell was visible as a black body. Photographs were taken using an Olympus inverted phase-contrast microscope equipped with Quick Imaging system. Cell motility was evaluated by measuring the areas free of the gold particles using NIH Image 1.63.
Statistical analysis
Data were expressed as means7s.d. and statistically subjected to Student's unpaired t-test. A level of Po0.05 was considered to be significant.
